GLPwatch
Papers (9189)
Page 31 of 154, ranked by citation count.
- Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
- Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
- Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
- No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.
- Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.
- Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
- Spinal microglial β-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain.
- Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
- Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
- Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.
- Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
- Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
- GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome.
- LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells.
- Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats.
- Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.
- Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.
- Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function.
- Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
- Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.
- A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications.
- Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
- Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
- Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).
- The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.
- GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
- The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation.
- Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices.
- Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
- Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
- Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
- Glucose-responsive hydrogel enhances the preventive effect of insulin and liraglutide on diabetic nephropathy of rats.
- Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
- Proteomic changes upon treatment with semaglutide in individuals with obesity.
- GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice.
- Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats.
- Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway.
- Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
- Acute pancreatitis associated with liraglutide.
- Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
- Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model.
- 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.
- Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
- Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
- Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
- Updates on cardiovascular outcome trials in diabetes.
- Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.
- Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
- Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
- The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type Ⅱ collagen and aggrecan in human SW1353 chondrocytes.
- Dulaglutide: first global approval.
- Improvement of Transdermal Delivery of Exendin-4 Using Novel Tip-Loaded Microneedle Arrays Fabricated from Hyaluronic Acid.
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
- Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
- Acute Kidney Injury Associated With Semaglutide.
- Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.
- Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist.
- Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
- Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts.